These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6344985)

  • 1. Pharmaceutics. Old regulations, new enforcement.
    Reich SD
    Cancer Nurs; 1983 Jun; 6(3):229-30. PubMed ID: 6344985
    [No Abstract]   [Full Text] [Related]  

  • 2. Laetrilomania--again.
    Relman AS
    N Engl J Med; 1978 Jan; 298(4):215-6. PubMed ID: 339088
    [No Abstract]   [Full Text] [Related]  

  • 3. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
    [No Abstract]   [Full Text] [Related]  

  • 4. Orphan products activities of the National Institutes of Health.
    Schepartz SA
    Prog Clin Biol Res; 1983; 127():173-86. PubMed ID: 6889399
    [No Abstract]   [Full Text] [Related]  

  • 5. Investigational new drugs in cancer chemotherapy.
    Peterson BA; Briscoe K
    Minn Med; 1979 Jul; 62(7):536-8. PubMed ID: 386073
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trials: a recent emphasis in the prevention program of the National Cancer Institute.
    DeWys WD; Greenwald P
    Semin Oncol; 1983 Sep; 10(3):360-4. PubMed ID: 6665563
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trials referral resource. Current clinical trials of G3139.
    Tock B; Zwiebel JA; Schoenfeldt M
    Oncology (Williston Park); 2003 Sep; 17(9):1244-6, 1251-3, 1258. PubMed ID: 14569852
    [No Abstract]   [Full Text] [Related]  

  • 8. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.
    Sheikh N
    Curr Opin Mol Ther; 2003 Aug; 5(4):428-32. PubMed ID: 14513687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenge to growth hormone trial.
    Lehrman S
    Nature; 1993 Jul; 364(6434):179. PubMed ID: 8321300
    [No Abstract]   [Full Text] [Related]  

  • 10. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 12. Slow start to phase 0 as researchers debate value.
    Twombly R
    J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
    [No Abstract]   [Full Text] [Related]  

  • 13. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

  • 16. [Soviet-American cooperation in experimental and clinical chemotherapy from 1972 to 1979].
    Peredovchikova NI; Kiselev AV; Puchkov IuI; Komarova LE; Gorbunova VA
    Vopr Onkol; 1980; 26(12):3-6. PubMed ID: 7008350
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
    Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials referral resource. Current clinical trials of bortezomib.
    Wright JJ; Zerivitz K; Schoenfeldt M
    Oncology (Williston Park); 2003 May; 17(5):677-80, 683-6, 691-2. PubMed ID: 12800794
    [No Abstract]   [Full Text] [Related]  

  • 20. Flasks, fibres and flanks--pre-clinical tumour models for predicting clinical antitumour activity.
    Newell DR
    Br J Cancer; 2001 May; 84(10):1289-90. PubMed ID: 11355935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.